All In Biotech

Drug Trial Radar · NCT06313086

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303c Versus Trastuzumab Emtansine in Patients With HER2-positive Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 442 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

442

Planned (sponsor's estimate)

Start

Mar 13, 2024

Primary completion

Dec 2025

Study completion Feb 2028

Sponsor

Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer

Conditions

  • HER2-positive Breast Cancer

Interventions

  • DP303cDrug

    intravenous injection

  • trastuzumab emtansineDrug

    intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) by BIRCTime frame: Up to approximately 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.